文献速递慢性肾脏病肾血管病与高血压

螺内酯与氯噻酮对慢性肾脏病心血管结构及功能的影响:随机开放标签试验

Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2021-08-30

本研究为前瞻性随机开放标签盲终点试验,纳入154例非糖尿病2-3期CKD患者,比较螺内酯25mg与氯噻酮25mg每日一次治疗40周对左心室质量的影响。结果显示两组左心室质量回归无显著差异,血压和脉搏波速度也无显著差异,但螺内酯组高钾血症发生率更高。

要点

  • 螺内酯与氯噻酮在降低左心室质量方面无显著差异(调整均差-3.8g,P=0.08)
  • 两药降压效果相当,脉搏波速度无显著差异(调整均差0.04m/s,P=0.90)
  • 螺内酯组高钾血症(≥5.4mEq/L)更常见(12例 vs 2例,调整RR 5.5,P=0.02)

核心结论

  • 在非糖尿病CKD患者中,螺内酯在降低左心室质量、血压或动脉僵硬度方面并不优于氯噻酮。

研究设计与样本

  • 前瞻性、随机、开放标签、盲终点研究,在英国四个中心进行。
  • 纳入154例非糖尿病2期和3期CKD患者(eGFR 30-89 ml/min per 1.73 m2)。
  • 比较螺内酯25 mg与氯噻酮25 mg每日一次治疗40周。
  • 主要终点为心脏磁共振成像测量的左心室质量变化。

主要发现

  • 第40周时,螺内酯 compared with 氯噻酮的左心室质量调整均差为-3.8 g(95% CI -8.1至0.5 g,P=0.08)。
  • 两药均降低诊室和24小时动态血压,组间无显著差异。
  • 第40周时脉搏波速度调整均差为0.04 m/s(95% CI -0.4至0.5 m/s,P=0.90)。
  • 高钾血症(≥5.4 mEq/L)在螺内酯组更常见(12例 vs 2例),调整相对风险为5.5(95% CI 1.4至22.1,P=0.02)。
  • eGFR下降>30%在氯噻酮组有8例,螺内酯组有2例,调整相对风险为0.2(95% CI 0.05至1.1,P=0.07)。

关键数值与推荐

  • 参与者正在接受血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂治疗,血压控制目标≤130/80 mm Hg。
  • 高钾血症定义为≥5.4 mEq/L,未报告严重高钾血症(≥6.5 mEq/L)患者。

临床怎么用

  • 在已使用ACEI或ARB且血压控制良好的非糖尿病CKD患者中,螺内酯与氯噻酮降压及改善心血管结构效果相当。
  • 使用螺内酯时需监测血钾,高钾血症风险较氯噻酮更高。

局限性

  • 开放标签设计可能引入偏倚。
  • 样本量较小(154例),可能不足以检测左心室质量的微小差异。
  • 研究仅纳入非糖尿病2-3期CKD患者,结果不能推广至其他CKD人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: In a randomized double-blind, placebo-controlled trial, treatment with spironolactone in early-stage CKD reduced left ventricular mass and arterial stiffness compared with placebo. It is not known if these effects were due to BP reduction or specific vascular and myocardial effects of spironolactone. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A prospective, randomized, open-label, blinded end point study conducted in four UK centers (Birmingham, Cambridge, Edinburgh, and London) comparing spironolactone 25 mg to chlorthalidone 25 mg once daily for 40 weeks in 154 participants with nondiabetic stage 2 and 3 CKD (eGFR 30-89 ml/min per 1.73 m2). The primary end point was change in left ventricular mass on cardiac magnetic resonance imaging. Participants were on treatment with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and had controlled BP (target ≤130/80 mm Hg). RESULTS: There was no significant difference in left ventricular mass regression; at week 40, the adjusted mean difference for spironolactone compared with chlorthalidone was -3.8 g (95% confidence interval, -8.1 to 0.5 g, P=0.08). Office and 24-hour ambulatory BPs fell in response to both drugs with no significant differences between treatment. Pulse wave velocity was not significantly different between groups; at week 40, the adjusted mean difference for spironolactone compared with chlorthalidone was 0.04 m/s (-0.4 m/s, 0.5 m/s, P=0.90). Hyperkalemia (defined ≥5.4 mEq/L) occurred more frequently with spironolactone (12 versus two participants, adjusted relative risk was 5.5, 95% confidence interval, 1.4 to 22.1, P=0.02), but there were no patients with severe hyperkalemia (defined ≥6.5 mEq/L). A decline in eGFR >30% occurred in eight participants treated with chlorthalidone compared with two participants with spironolactone (adjusted relative risk was 0.2, 95% confidence interval, 0.05 to 1.1, P=0.07). CONCLUSIONS: Spironolactone was not superior to chlorthalidone in reducing left ventricular mass, BP, or arterial stiffness in nondiabetic CKD.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Edwards NC, Price AM, Mehta S, et al. Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial. Clin J Am Soc Nephrol. 2021. PMID: 34462286. doi:10.2215/CJN.01930221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。